Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

CompletedOBSERVATIONAL
Enrollment

544

Participants

Timeline

Start Date

February 1, 2016

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions
Epilepsy With POS With or Without Secondary Generalization
Trial Locations (44)

Unknown

Ep0077 4504, Aarhus

Ep0077 4501, Glostrup Municipality

Ep0077 4503, Odense

Ep0077 4906, Berlin

Ep0077 4910, Bonn

Ep0077 4909, Freiburg im Breisgau

Ep0077 4913, Hamburg

Ep0077 4901, Kork

Ep0077 4912, Radeberg

Ep0077 4904, Ravensburg

Ep0077 4905, Tübingen

Ep0077 3605, Budapest

Ep0077 3608, Kecskemét

Ep0077 3607, Mosdós

Ep0077 3602, Nyíregyháza

Ep0077 3601, Pécs

Ep0077 3606, Szeged

Ep0077 3503, Cork

Ep0077 3501, Dublin

Ep0077 3505, Dublin

Ep0077 3912, Florence

Ep0077 3901, Milan

Ep0077 3904, Milan

Ep0077 3902, Verona

Ep0077 3101, Heeze

Ep0077 3102, Maastricht

Ep0077 4701, Fredrikstad

Ep0077 3402, A Coruña

Ep0077 3416, Badajoz

Ep0077 3412, Córdoba

Ep0077 3410, Murcia

Ep0077 4408, Birmingham

Ep0077 4414, Cardiff

Ep0077 4406, Dundee

Ep0077 4401, Glasgow

Ep0077 4417, Inverness

Ep0077 4404, Leeds

Ep0077 4409, London

Ep0077 4411, London

Ep0077 4403, Salford

Ep0077 4407, Sheffield

Ep0077 4412, Stoke-on-Trent

Ep0077 4416, Swansea

Ep0077 4402, Truro

Sponsors
All Listed Sponsors
collaborator

Pharm Research Associates Ltd. UK

INDUSTRY

lead

UCB Biopharma S.P.R.L.

INDUSTRY